WallStreetZenWallStreetZen

NASDAQ: EGRX
Eagle Pharmaceuticals Inc Stock

$3.82+0.15 (+4.09%)
Updated Jun 13, 2024
EGRX Price
$3.82
Fair Value Price
N/A
Market Cap
$49.61M
52 Week Low
$3.21
52 Week High
$23.52
P/E
4.15x
P/B
0.2x
P/S
0.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$257.55M
Earnings
$11.95M
Gross Margin
69.8%
Operating Margin
13.69%
Profit Margin
4.6%
Debt to Equity
0.61
Operating Cash Flow
-$9M
Beta
0.75
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

EGRX Overview

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EGRX was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EGRX is good value based on its earnings relative to its share price (4.15x), compared to the US market average (30.48x)
P/E vs Market Valuation
EGRX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more EGRX due diligence checks available for Premium users.

Be the first to know about important EGRX news, forecast changes, insider trades & much more!

EGRX News

Valuation

EGRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
4.15x
Industry
1.36x
Market
30.48x
EGRX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EGRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

EGRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.2x
Industry
2.16x
EGRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EGRX's financial health

Profit margin

Revenue
$64.6M
Net Income
$5.2M
Profit Margin
8%
EGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EGRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$404.8M
Liabilities
$152.8M
Debt to equity
0.61
EGRX's short-term assets ($187.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EGRX's short-term assets ($187.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EGRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$126.0k
Investing
-$6.0k
Financing
-$6.4M
EGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EGRX vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
EGRX$49.61M+4.09%4.15x0.20x
IXHL$50.00M-2.48%N/A3.54x
BGXX$52.11M-4.86%-3.91x4.69x
DRRX$52.46M+8.33%-2.04x6.32x
RMTI$55.78M-2.90%-5.11x2.70x

Eagle Pharmaceuticals Stock FAQ

What is Eagle Pharmaceuticals's quote symbol?

(NASDAQ: EGRX) Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol EGRX. Eagle Pharmaceuticals stock quotes can also be displayed as NASDAQ: EGRX.

If you're new to stock investing, here's how to buy Eagle Pharmaceuticals stock.

What is the 52 week high and low for Eagle Pharmaceuticals (NASDAQ: EGRX)?

(NASDAQ: EGRX) Eagle Pharmaceuticals's 52-week high was $23.52, and its 52-week low was $3.21. It is currently -83.76% from its 52-week high and 19% from its 52-week low.

How much is Eagle Pharmaceuticals stock worth today?

(NASDAQ: EGRX) Eagle Pharmaceuticals currently has 12,986,971 outstanding shares. With Eagle Pharmaceuticals stock trading at $3.82 per share, the total value of Eagle Pharmaceuticals stock (market capitalization) is $49.61M.

Eagle Pharmaceuticals stock was originally listed at a price of $12.83 in Feb 12, 2014. If you had invested in Eagle Pharmaceuticals stock at $12.83, your return over the last 10 years would have been -70.23%, for an annualized return of -11.41% (not including any dividends or dividend reinvestments).

How much is Eagle Pharmaceuticals's stock price per share?

(NASDAQ: EGRX) Eagle Pharmaceuticals stock price per share is $3.82 today (as of Jun 13, 2024).

What is Eagle Pharmaceuticals's Market Cap?

(NASDAQ: EGRX) Eagle Pharmaceuticals's market cap is $49.61M, as of Jun 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Eagle Pharmaceuticals's market cap is calculated by multiplying EGRX's current stock price of $3.82 by EGRX's total outstanding shares of 12,986,971.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.